Device Week, 9 June 2021 – ATTD Medtronic Update; CVRx IPO

In this week’s podcast, Medtech Insight's UK-based reporter Barnaby Pickering provides an update on Medtronic’s MiniMed 780G insulin pump cost-savings study, presented at the Advances Technologies & Treatments for Diabetes (ATTD) conference. US Commercial and R&D manager, Reed Miller, highlights details on CVRx’s recent IPO. Medtech Insight articles addressing topics discussed in this episode: ATTD 2021: Despite High Upfront Cost, Medtronic’s 780G Could Offer Cost Savings https://medtech.pharmaintelligence.informa.com/MT144044/ATTD-2021-Despite-High-Upfront-Cost-Medtronics-780G-Could-Offer-Cost-Savings CVRx Raises $75M In IPO To Commercialize And Develop Heart Failure Therapy https://medtech.pharmaintelligence.informa.com/MT144039/CVRx-Raises-$75M-In-IPO-To-Commercialize-And-Develop-Heart-Failure-Therapy For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR